# Neoadjuvant Pembrolizumab Plus Chemotherapy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma

> **NCT05302011** · PHASE2 · COMPLETED · sponsor: **Peking Union Medical College Hospital** · enrollment: 28 (actual)

## Conditions studied

- Esophageal Squamous Cell Carcinoma

## Interventions

- **DRUG:** Pembrolizumab
- **DRUG:** Carboplatin or Cisplatin
- **DRUG:** Docetaxel

## Key facts

- **NCT ID:** NCT05302011
- **Lead sponsor:** Peking Union Medical College Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-06-01
- **Primary completion:** 2023-03-30
- **Final completion:** 2023-06-30
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2023-10-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05302011

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05302011, "Neoadjuvant Pembrolizumab Plus Chemotherapy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05302011. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*